SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
BioTie Therapies Corp.'s Tozadenant (SYN115) Meets Primary and Multiple Secondary Endpoints in Phase 2b Study in Parkinson's Disease